Israeli startup Salignostics, the developer and provider of rapid saliva-based tests for the early detection of pregnancy, as well as COVID-19, cardiac risk, malaria, and other diseases, has closed an $8 million Series A financing round from private investors headed by angel investor Avigdor Orlinsky, the company announced Wednesday.
Follow Israel Hayom on Facebook, Twitter, and Instagram
Salignostics was founded in 2016 by a team of researchers at the Hebrew University of Jerusalem: Professor Aaron Palmon, currently head of the Authority of Research Students in Experimental Sciences at the Hebrew University; Dr. Omer Deutsch, who serves as CEO; Dr. Guy Krief, who serves as Deputy CEO and Director of Business Development; Dr. Raluca Cohen, who serves as Chief Scientific Officer; and Dr. Yoav Neumann, who serves as Senior Researcher.
Salignostics' kits provide home tests by means of a simple saliva test that takes only a few minutes. The company's technology relies on breakthrough scientific capabilities in rapid diagnostic tests by individuals, based on decades of research.
The company has raised a total of $16 million to date.
